Suppr超能文献

成年低级别胶质瘤患者术后5年随访期内肿瘤进展的预测因素

Predictors of tumor progression of low-grade glioma in adult patients within 5 years follow-up after surgery.

作者信息

Yan Zhiqiang, Wang Jiang, Dong Qiufeng, Zhu Lian, Lin Wei, Jiang Xiaofan

机构信息

Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.

出版信息

Front Surg. 2022 Oct 5;9:937556. doi: 10.3389/fsurg.2022.937556. eCollection 2022.

Abstract

BACKGROUND

Glioma originates from glial cells in the brain and is the most common primary intracranial tumor. This study intends to use a retrospective analysis to explore the factors that can predict tumor progression in adult low-grade gliomas, namely WHO II grade patients, within 5 years after surgery.

METHODS

Patients with WHO grade II glioma who were surgically treated in our hospital from February 2011 to May 2017 were included. According to the inclusion and exclusion criteria, 252 patients were included in the final analysis. According to the results of the 5-year follow-up (including survival and imaging review results), patients were divided into progression-free group and progression group. Univariate and multivariate analysis were conducted to investigate the related factors of tumor progression during the 5-year follow-up.

RESULTS

The results of the 5-year follow-up showed that 111 (44.0%) cases had no progress (progression free group, PFG), 141 (56.0%) cases had progress (progression group, PG), of which 43 (30.5%) cases were operated again, 37 cases (26.2%) received non-surgical treatments. There were 26 (10.3%) all-cause deaths, and 21 (8.3%) tumor-related deaths. Univariate and multivariate analysis showed that age >45 years old (OR = 1.35, 95% CI, 1.07-3.19,  = 0.027), partial tumor resection (OR = 1.66, 95% CI, 1.15-3.64,  = 0.031), tumor diameter >3 cm (OR = 1.52, 95% CI, 1.14-4.06,  = 0.017) and no radiotherapy (OR = 1.37, 95% CI, 1.12-2.44,  = 0.039) were independent predictors of the progression of tumor during the 5-year follow-up period.

CONCLUSION

Age >45 years old, partial tumor resection, tumor diameter >3 cm, no radiotherapy are predictors for tumor progression for glioma patients after surgery.

摘要

背景

胶质瘤起源于脑内的胶质细胞,是最常见的原发性颅内肿瘤。本研究旨在采用回顾性分析方法,探讨可预测成人低级别胶质瘤(即世界卫生组织II级患者)术后5年内肿瘤进展的因素。

方法

纳入2011年2月至2017年5月在我院接受手术治疗的世界卫生组织II级胶质瘤患者。根据纳入和排除标准,最终纳入252例患者进行分析。根据5年随访结果(包括生存情况和影像学复查结果),将患者分为无进展组和进展组。进行单因素和多因素分析,以研究5年随访期间肿瘤进展的相关因素。

结果

5年随访结果显示,111例(44.0%)无进展(无进展组,PFG),141例(56.0%)有进展(进展组,PG),其中43例(30.5%)再次手术,37例(26.2%)接受非手术治疗。全因死亡26例(10.3%),肿瘤相关死亡21例(8.3%)。单因素和多因素分析显示,年龄>45岁(OR = 1.35,95%CI,1.07 - 3.19,P = 0.027)、肿瘤部分切除(OR = 1.66,95%CI,1.15 - 3.64,P = 0.

相似文献

1
Predictors of tumor progression of low-grade glioma in adult patients within 5 years follow-up after surgery.
Front Surg. 2022 Oct 5;9:937556. doi: 10.3389/fsurg.2022.937556. eCollection 2022.
3
Insular glioma resection: assessment of patient morbidity, survival, and tumor progression.
J Neurosurg. 2010 Jan;112(1):1-9. doi: 10.3171/2009.6.JNS0952.
4
Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma.
Cochrane Database Syst Rev. 2019 Aug 5;8(8):CD013047. doi: 10.1002/14651858.CD013047.pub2.
5
Surgical management of incidentally discovered diffusely infiltrating low-grade glioma.
J Neurosurg. 2018 Jul;129(1):19-26. doi: 10.3171/2017.3.JNS17159. Epub 2017 Oct 6.
6
Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas.
J Neurosurg. 2010 Jan;112(1):10-7. doi: 10.3171/2008.10.JNS08608.
8
Risk factors for early progression of diffuse low-grade glioma in adults.
Chin Neurosurg J. 2022 Oct 1;8(1):25. doi: 10.1186/s41016-022-00295-z.
10
Increased signal intensity in FLAIR sequences in the resection cavity can predict progression and progression-free survival in gliomas.
Neurocirugia (Astur). 2016 Nov-Dec;27(6):269-276. doi: 10.1016/j.neucir.2016.04.002. Epub 2016 May 24.

本文引用的文献

1
Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Front Immunol. 2022 May 23;13:899710. doi: 10.3389/fimmu.2022.899710. eCollection 2022.
2
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
3
Low-Grade Glioma Case Series: Lessons Learned from an Evolving 10-Year Single-Institution Multidisciplinary Team Practice.
World Neurosurg. 2021 Jul;151:e47-e57. doi: 10.1016/j.wneu.2021.03.101. Epub 2021 Mar 26.
5
Neutrophil-to-Lymphocyte Ratio and Its Changes are Related to Grade II-IV Glioma Recurrence.
Cancer Manag Res. 2020 Sep 30;12:9429-9434. doi: 10.2147/CMAR.S267523. eCollection 2020.
6
Current clinical management of elderly patients with glioma.
Expert Rev Anticancer Ther. 2020 Dec;20(12):1037-1048. doi: 10.1080/14737140.2020.1828867. Epub 2020 Oct 8.
7
Risk Stratification in Low Grade Glioma: A Single Institutional Experience.
Neurol India. 2020 Jul-Aug;68(4):803-812. doi: 10.4103/0028-3886.293441.
8
Establishment of age group classification for risk stratification in glioma patients.
BMC Neurol. 2020 Aug 20;20(1):310. doi: 10.1186/s12883-020-01888-w.
9
Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic development.
Expert Rev Anticancer Ther. 2020 May;20(5):355-363. doi: 10.1080/14737140.2020.1757440. Epub 2020 May 12.
10
Multimodality Imaging Techniques to Assist Surgery in Low-Grade Gliomas.
World Neurosurg. 2020 Jan;133:423-425. doi: 10.1016/j.wneu.2019.10.120.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验